Form 4: CG Oncology Director Victor Tong Jr. Granted 24,165 Stock Options

CG Oncology, Inc. Director and 10% Owner Victor Edward Tong Jr. was granted 24,165 stock options with an exercise price of $26.63, vesting monthly over one year.

Summary

• Victor Edward Tong Jr., a Director and 10% Owner of CG Oncology, Inc. (CGON), was granted 24,165 stock options.
• The stock options have an exercise price of $26.63 per share.
• The grant date for these options was June 5, 2025, and they are set to expire on June 4, 2035.
• The options will vest monthly, with 1/12th of the total shares vesting each month following June 5, 2025, contingent upon Mr. Tong's continuous service to the Issuer.
• An accelerated vesting clause states that any remaining unvested portion of the stock option will vest on the date of the next annual meeting of the Issuer's stockholders, if it occurs prior to the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates alignment of director's interests with shareholders through equity compensation, which is a standard and generally favorable practice.

Positives

• The grant of stock options to a director aligns their financial interests with those of the company's shareholders, incentivizing long-term value creation and performance.
• The vesting schedule encourages the director's continued commitment and service to CG Oncology, Inc.

Negatives

• No immediate negative implications are apparent from this stock option grant.
• Potential future dilution of existing shares if and when these options are exercised, which is a standard aspect of equity compensation.

Future Outlook

The vesting schedule indicates that the options will vest monthly over the next year, subject to the director's continuous service, aligning future compensation with ongoing performance and strategic objectives.

Industry Context

This Form 4 filing details an individual insider transaction, specifically the grant of stock options as part of director compensation. Such grants are a common practice across various industries to align management and board interests with shareholder value, rather than reflecting broader industry trends.

Related Party Transactions

• The grant of stock options to Victor Edward Tong Jr., a Director and 10% Owner, constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value creation, potentially leading to improved company performance. However, it also introduces potential future dilution if the options are exercised.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The stock options will continue to vest monthly following June 5, 2025, subject to the director's continuous service.
• The options may be exercised by the reporting person upon vesting, up until the expiration date of June 4, 2035.

Key Dates

Keywords

CG Oncology, CGON, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Victor Edward Tong Jr.